We are on vacation until December 31st. Thank you for being patient and considerate.

Current Treatment Options for Fuchs Endothelial Dystrophy, ISBN-13: 978-3319430195




  • Format: PDF
  • Publisher: ‎ Springer; 1st ed. 2017 edition (November 11, 2016)
  • Language: ‎ English
  • 263 pages
  • ISBN-10: ‎ 331943019X
  • ISBN-13: ‎ 978-3319430195


This book provides state of the art information on modern minimally invasive lamellar transplant techniques for Fuchs endothelial dystrophy (FED), such as Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK). In addition to clear step-by-step descriptions of procedures, guidance is offered on donor tissue preparation, potential intra- and postoperative complications, and complication management. Future treatment options in the form of medical, cell-based approaches are also discussed. To complete the picture, relevant information is included on the pathophysiology, clinical features, and differential diagnosis of FED. This book will be of interest to all who wish to learn about the dramatic developments in corneal transplantation and medical treatment that are transforming the management of FED.

Claus Cursiefen, MD, PhD, is Chairman and Professor in the Department of Ophthalmology at the University of Cologne, Germany and Adjunct Associate Scientist with the Schepens Eye Research Institute/Harvard Medical School, Boston. After completing his MD thesis at the Department of Anatomy, University of Würzburg, Dr. Cursiefen undertook a residency in the Department of Ophthalmology, Erlangen and a postdoctoral fellowship at the Schepens Eye Research Institute in Boston, MA. His clinical focus encompasses modern lamellar corneal transplant techniques (DMEK, DALK, DSAEK), artificial cornea, ocular surface reconstruction, cataract and glaucoma surgery, curative and refractive laser surgery, and ophthalmo-oncology. Dr. Cursiefen’s research has concentrated especially on mechanisms of corneal hem- and lymphangiogenesis and their implications for corneal transplant immunology. He is the author of more than 250 publications in the field, including in PNAS, Journal of Experimental Medicine, Journal of Clinical Investigation, and Nature Medicine.

Albert S. Jun, MD, PhD, is a board-certified opththalmologist who works at The Johns Hopkins Hospital, Baltimore, MD, USA,  and is Associate Professor of Ophthalmology at The Johns Hopkins University School of Medicine. He is also Associate Professor of Ophthalmology and Vice Chair for Education at the Wilmer Eye Institute. After gaining his PhD from Emory University Graduate School of Arts and Sciences, focusing on Genetics and Molecular Biology, Dr. Jun completed an Ophthalmology Residency at The Johns Hopkins Medical Institutions (1998–2001), a Cornea and External Disease Fellowship at Moorfields Eye Hospital (London, UK) (2001–2), and a Corneal Gene Therapy Research Fellowship at Imperial College School of Medicine (London, UK) (2002). He became a Diplomate of the  American Board of Ophthalmology in 2003. In 2013 he received an Achievement Award from the American Academy of Ophthalmology and was International Visiting Professor on the occasion of the 150th Anniversary of the Department of Ophthalmology, Medical University of Graz, Austria. More recently he was International Visiting Professor at the Bowman Corneal Club, Liverpool (UK). Dr. Jun is a member of the editorial board of Cornea: The Journal of Cornea and External Disease. He is lead or co-author of approximately 60 peer-reviewed publications.


There are no reviews yet.

Be the first to review “Current Treatment Options for Fuchs Endothelial Dystrophy, ISBN-13: 978-3319430195”

Your email address will not be published. Required fields are marked *